Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

I’m walking in the Eifel Mountains in western Germany, through cathedral-like groves of oak and beech, and there’s a strange unmoored feeling of entering a fairy tale. The trees have become vibrantly ...

Hardwoods, known as broadleafs, are trees classed as angiosperms with ovules enclosed for fruit protection. When appropriately watered on good fertile sites or fed in the landscape with a unique tree ...